Gemcitabine Hydrochloride Market Report 2026-2030 & 2035 Featuring Strategic Analysis of Fresenius Kabi, Eli Lilly and Company, Teva Pharma, Intas Pharma, Mylan and More
Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Gemcitabine Hydrochloride Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides detailed statistics on global market size, competitor shares, detailed segments, and evolving trends.
The global gemcitabine hydrochloride market is forecasted to grow significantly, expanding from $0.83 billion in 2025 to $0.89 billion in 2026, with a CAGR of 6.7%. Continued growth is projected, with market value reaching $1.15 billion in 2030 at a CAGR of 6.6%. This growth is driven by advances in combination oncology therapies, improved cancer care infrastructure, rising solid tumor cases, biosimilar development, and wider access to oncology drugs. Key trends include an increase in combination chemotherapy use, demand for injectable oncology drugs, hospital-based cancer treatments, precision oncology, and adoption across various cancer types.
Breast cancer instances are set to significantly impact market growth, as increasing life expectancy and subsequent genetic mutations raise disease risk. Gemcitabine hydrochloride is pivotal in breast cancer treatment, effectively slowing malignant cell proliferation by disrupting DNA replication. The International Agency for Research on Cancer projects breast cancer diagnoses to reach 3.2 million per year by 2050, further supporting market expansion.
Innovative treatments, such as perioperative immunotherapy, are transforming cancer care. Notably, AstraZeneca received FDA approval for Imfinzi (durvalumab) in March 2025, enhancing treatment efficacy for muscle-invasive bladder cancer (MIBC) through combined perioperative and chemotherapy approaches. Clinical trials show improved survival rates and reduced recurrence risk with this treatment.
The market dynamics include strategic mergers and acquisitions, highlighted by Cheplapharm's acquisition of Gemzar from Eli Lilly in December 2024, expanding its oncology drug portfolio. Leading companies in this market include Fresenius Kabi, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., and more.
Geographically, North America was the largest market in 2025, with Asia-Pacific anticipated to lead growth through the forecast period. Comprehensive regional analysis includes Asia-Pacific, Southeast Asia, Europe, North America, South America, the Middle East, and Africa. Impacted by tariffs, North American and European markets have faced increased costs in chemotherapy drug segments, whereas Asia-Pacific manufacturers have experienced pricing pressures. Nevertheless, tariffs have catalyzed domestic API manufacturing and strengthened oncology drug supply chains.
Key Advantages of the Report:
Report Scope:
Key Attributes
The companies featured in this Gemcitabine Hydrochloride market report include:
For more information about this report visit https://www.researchandmarkets.com/r/v64txj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment